This content is intended for healthcare professionals only in Europe.

Please confirm that you are an EU healthcare professional.

Decline

This promotional activity has been sponsored by Jazz Pharmaceuticals. Jazz Pharmaceuticals provided financial support for this activity and has had input into the selection of the faculty and the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Prescribing Information

Leukaemia View Time: 50 mins

touchSYMPOSIUM HIGHLIGHTS Treatment decisions in high-risk* acute myeloid leukaemia: what is the ultimate goal?

Watch leading experts present and discuss the latest developments in the assessment and treatment of high-risk* acute myeloid leukaemia.

*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

  • Symposium Presentations
Is treatment with curative intent the ultimate goal?
Is intensive chemotherapy the antileukaemic standard of care?
How should MRD assessment inform treatment decisions?
Pursuing long-term survival in the real world
 
Overview

High-risk* acute myeloid leukaemia (AML) has a poor prognosis and remains a therapeutic challenge.1 In this sponsored Symposium, leading experts present and discuss the latest developments in the assessment and treatment of high-risk AML, including the importance of measurable residual disease and the use of Vyxeos Liposomal (CTX-351).2–4

*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Prof. Mohamad Mohty

Professor and Head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital, University Pierre & Marie Curie, Paris, France  read more

Prof. Thomas Cluzeau

Professor and Head of the Department of Haematology at CHU of Nice, Côte d’Azur University, Nice, France

Prof. Martin Bornhӓuser

Professor of Haematology at the University Hospital Carl Gustav Carus, Dresden, Germany

Prof. Gert Ossenkoppele

Professor of Hematology at the VU University Medical Center, Amsterdam, The Netherlands

Prof. Adriano Venditti

Professor of Haematology at the University of Rome Tor Vergata, Rome, Italy

Prof. Thomas Schroeder

Head of Stem Cell Transplantation, University Hospital Essen, Essen, Germany

Disclosures

Prof. Mohamad Mohty

Honoraria: Adaptive Biotechnologies, Amgen, Astellas, Celgene-BMS, GSK, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, Oncopeptides, Pfizer, Sanofi & Takeda.  Research/project funding: Janssen & Sanofi.

Prof. Thomas Cluzeau

Advisory board: AbbVie, Agios, BMS-Celgene, Jazz Pharmaceuticals, Novartis & Servier.  Invited speaker/education: Amgen, Astellas, BMS-Celgene, Jazz Pharmaceuticals, Novartis, Pfizer & Sanofi.  Research/project funding: Alexion, Amgen, Aprea, Arog, BMS-Celgene, Jazz Pharmaceuticals, Kartos, Novartis & Syros.

Prof. Martin Bornhӓuser

Advisory board: Alexion, Jazz Pharmaceuticals,  Merck Sharp & Dohme. Honoraria: BMS-Celgene, Jazz Pharmaceuticals, Merck Sharp & Dohme. Novartis. Research/project funding: Miltenyi Biotec.

Prof. Gert Ossenkoppele

Advisory board: Agios Pharmaceuticals, Amgen, Astellas, Bristol Myers Squibb, Celgene, Gilead, Jazz Pharmaceuticals, Johnson & Johnson, MERUS, Novartis, Pfizer & Roche. Consultancy: Celgene, Johnson & Johnson, Roche.  Research/project funding: Celgene, Johnson & Johnson, Novartis.

Prof. Adriano Venditti

Consultancy: AbbVie, Amgen, Astellas, AstraZeneca, Janssen, Jazz Pharmaceuticals, Medac, Novartis & Pfizer.  Invited speaker/education: AbbVie, AstraZeneca, BMS-Celgene, Janssen & Jazz Pharmaceuticals. Project/research funding: Sandoz.

Prof. Thomas Schroeder

Consultancy: AbbVie, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Pfizer & Takeda.  Invited speaker/education: AbbVie; Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Pfizer & Takeda.  Honoraria: AbbVie, Bristol Myers Squibb, Celgene & Jazz Pharmaceuticals.  Project/research: Celgene-BMS & Jazz Pharmaceuticals.

Leave Feedback
Learning Objectives & Overview
Overview

High-risk* acute myeloid leukaemia (AML) has a poor prognosis and remains a therapeutic challenge.1 In this sponsored Symposium, recorded at the 5th Annual Meeting of the International Academy for Clinical Haematology, six leading experts present and discuss key aspects of high-risk AML treatment, including the importance of measurable residual disease, and clinical/real-world evidence for the use of Vyxeos Liposomal (Daunorubicin 44 mg / Cytarabine 100 mg)2–4

*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Learning Objectives

After watching this activity, participants should be better able to:

  • Describe the key treatment goals and factors influencing treatment decisions in high-risk* AML
  • Discuss the role of measurable residual disease in the management of high-risk* AML
  • Review the clinical and real-world evidence on the use of Vyxeos Liposomal (CTX-351) for the treatment of high-risk* AML
Adverse Events
Adverse Events

Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email to aereporting@jazzpharma.com

References
References
  1. Granfeldt Østgård LS, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641–9.
  2. Lancet JE, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481–e491.
  3. Chiche E, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5:176–184.
  4. Guolo F, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020;10:96.
Feedback Close
Feedback

Please provide feedback for this touchSYMPOSIUM HIGHLIGHTS on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72